Startup legal playbook•10 min read

Startup funding explained: types and strategies

Authors

  • Torys’ Emerging Companies and VC Group

Read this if: you’re thinking about a raise at any stage of your startup’s lifecycle

You might also like: Startup funding checklist: legal to-dos to make your investors happy

Go deeper: Raising capital

 
Startup capital comes in many forms, and the most appropriate one for your business depends on several factors. Below are the most common ways to finance a startup.

Bootstrapping

Bootstrapping is when a founder uses their own personal assets or business revenue to fund the operation and growth of the startup. This is common when the company is in its very early stages or cannot yet attract equity investment. This is sometimes referred to as pre-seed funding. Successful bootstrapping requires a tight adherence to budgets, keeping lean operating costs, and having a business plan for generating revenue quickly. Later-stage startups will sometimes use bootstrapping as a bridge between funding rounds.

Friends and family round

Another form of pre-seed funding is a friends and family round. As the name suggests, this involves receiving funding from friends and family rather than accredited investors. Many founders will offer friends and family an equity stake in their startup in exchange for funding. If you decide to do this, you must be mindful of how much equity, or future equity, you offer and clearly document each offer, or else you can come into issues regarding ownership or excessive unanticipated dilution as your startup grows.

Angel investment

Angel investors are individuals who make investments in startups for an equity stake or convertible debt, generally at earlier stages when there is still a large amount of risk. Accordingly, angel investors have a higher appetite for risk in their pursuit of a higher rate of return. These are accredited investors, and the capital they invest comes from their own net worth. It is common for a group of angel investors to invest together.

Venture capital

Venture capitalists (VCs) also make investments in companies for an equity stake; however, they use capital from an investment fund. The venture capital fund is capitalized by investors designated as limited partners and strategically managed by a general partner.

Stages of VC funding

The initial round of funding for a startup is sometimes referred to as seed funding, with subsequent funding rounds being referred to as series funding. Series funding ranges from Series A, B, C to D. Below are some general benchmarks relating to each series of funding:

  • Series A funding is raised by startups when they have traction (e.g., revenue, number of customers).
  • Series B funding is raised by startups that have product-market fit.
  • Series C funding is raised to allow market expansion, develop new products, or otherwise grow the business. This is often the last stage of funding before a company looks to IPO or be acquired.
  • Series D funding is sometimes raised if a company wants to raise its value before IPO, or it has identified further opportunities for which additional capital is needed.
Types of VC funding

Venture capitalists invest in startups in a few different ways, called instruments. The instrument you choose will depend on many factors, including how much money you're raising and your company’s expected growth trajectory. Pay careful consideration to the rights granted to investors in early-stage fundraising rounds, as mistakes made in these financings can cause issues down the road.

The most common instruments used for VC investments are SAFEs, convertible notes, and preferred share financings.

Simple agreement for future equity (SAFE)

A SAFE gives the investor the right to future equity in your startup following the company’s completion of a qualifying priced round of financing in exchange for their immediate, early investment. This is the simplest agreement used in the market to raise funding for early-stage companies and is most appropriate for bridge rounds or rounds that are raising less than $2M.

The biggest advantage of using a SAFE is that you and the investor don't need to agree on the exact valuation of your company at the date of the agreement. This is very valuable for early-stage startups who might not have enough user data, traction, or revenue on which to base a valuation. A SAFE is a simpler, more standardized instrument than a convertible note and is quicker to put together, but it offers investors fewer protections and more limitations due to its simplicity.

A SAFE, like a convertible note, typically provides the investor with some form of economic benefit for their earlier investment in the company in the form of either (or both) a discount or valuation cap which affects the price per share at which the SAFE converts into shares at a later date. However, unlike a convertible note, a SAFE is treated as equity as opposed to debt on the company’s balance sheet. Because debt is repaid in priority to equity following a liquidation event of a company, this makes SAFEs an inherently riskier instrument of investment for investors, which can make them less desirable for them than convertible note instruments. That being said, if you sell your company while SAFEs are still outstanding (i.e., they have not yet been converted into shares), they will be senior to the common shares (which is the class of shares typically held by founders). This means that the SAFEs need to be paid out prior to the founders receiving any proceeds in an exit. You can find a sample SAFE here.

Convertible note

A convertible note is like a SAFE in that you can defer valuation to a future date, and it is most appropriate for bridge rounds or rounds that are raising less than $2M. The key difference is that convertible notes are more customized, have a maturity date and bear interest—so they are classified as debt rather than equity from an accounting perspective.

For this reason, early-stage, pre-revenue startups tend to avoid convertible notes in favour of SAFEs. Convertible notes are also less standardized than SAFEs, resulting in more negotiation between the parties. As in the case of a SAFE, convertible notes often include a discount or valuation cap as an economic incentive for investors to invest in advance of a priced round. You can find a sample convertible note here.

Preferred share financings

These instruments tend to be the venture capitalist’s instrument of choice. While preferred share financings are far more complex than SAFEs and convertible notes, they offer investors the most protection from an equity ownership perspective, understanding that debt continues to sit ahead of equity on the liquidation stack. Preferred shares are more appropriate for rounds that are more than $2M.

As their terms are usually heavily negotiated and require much more paperwork, you will spend a lot of time structuring the deal which can result in higher legal fees. This is another reason why this instrument is usually reserved for larger financing rounds.

Beyond VC instruments: Term sheets and cap tables

Regardless of the investment instrument, and the amount of capital to be invested, there are two key things that you need to include in your equity fundraising process: a term sheet and a pro forma cap table.

Term sheet

Term sheets are instrumental to the fundraising process as they summarize the principal terms of the deal. The purpose of the term sheet is to make sure that all parties are fully aligned on the key terms of the financing—which can include the financing amount, the type of instrument to be used (i.e., SAFE, convertible note or preferred share financing), the timeline to complete the financing, investor rights, the steps required to complete the transaction and who is responsible for each step.

Many founders will note that they have an agreement in principle with their investors and so they want to skip the tertiary stage and go straight to finalizing these documents in a bid to save time and money. However, this is almost always invariably more expensive, as there are legal fees related to negotiating the principal transaction documents, and the more negotiation involved the higher the fee. Therefore, you should spend time discussing and agreeing upon the terms of the deal with the investor at the term sheet stage (to make sure that everything you think has been settled is truly settled) before you incur costs related to the negotiation of the final transaction documents.

However, while it is recommended to have agreed upon the key rights and responsibilities that will be laid out in the term sheet before you engage legal counsel, it is important that you do not sign the term sheet until it has been reviewed by your lawyer. This is because the term sheet may include provisions that will result in you unknowingly conceding less obvious, but no less material, parts of your company.

Your lawyer’s job is to identify all scenarios and help you pick the best agreement for your startup. Sometimes founders will realize at the term sheet review stage that the terms offered do not align with what they are looking for; if this happens to you, you can negotiate the terms or not go through with the deal. Once the term sheet is settled, it will serve as a roadmap to your counsel when they are drafting other key transaction documents.

You can find a sample term sheet here.

Pro forma cap table

While the term sheet is being negotiated, you should also be thinking about your pro forma cap table and building out a model of the entire round. The pro forma cap table is designed to show you what your equity stake looks like post-financing. The reason why you want to build it up at the term sheet stage is that, as the negotiations evolve and the terms are changing, you can plug in each of the assumptions and changes and see what the impact is on your equity interest post-closing.

A common misconception is that this is only something you need to do for a priced round because at a convertible round you might not know exactly how the notes are going to convert. However, this kind of forecasting is relevant even in a convertible round or in a SAFE financing, because you can model in certain assumptions about the conversion and see what your equity stake would look like in even the worst-case scenario.

The pro forma cap table is one issue to consider when preparing for legal due diligence before you fundraise.

Venture debt

Venture debt is a loan that is secured by the startup’s assets. This kind of loan is offered to high-growth startups that have already received investment from VCs and is often used to complement equity raised. Venture debt helps to generate operating cash and is usually paid back in installments.

Strategic investors

Strategic investors, known as corporate venture capital (CVC), are usually a department or a separate subsidiary of a large operating company. A CVC invests directly from the company’s balance sheet, usually in a startup operating in the same or complementary industry. CVCs generally do not invest at the seed stage and instead invest at a later round. CVCs participate on the same customary terms and conditions as traditional VC investors and operate under standard VC documents and market terms.

This article focuses on general market terms; however, there is no one-size-fits all approach to funding agreements and individual deals may include their own unique features.


Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.

Développement de contre-mesures médicales au Canada

Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.

Exploiter les voies réglementaires mises en place lors de la pandémie de COVID-19

Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.

Le rôle de la Stratégie dans le renforcement du régime réglementaire de la santé au Canada

La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.

Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.

Prochaines étapes

Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.

Get to know our ECVC practice